Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario.
安大略省多倫多/ACCESSWIRE/2024年4月11日/專注於開發免疫炎症性疾病宿主導療法的臨床階段生物製藥公司Edesa Biotech, Inc.（納斯達克股票代碼：EDSA）今天宣佈，該公司將參與2024年Bloom Burton & Co.醫療保健投資者會議定於2024年4月16日至17日在安大略省多倫多舉行。
Edesa's Chief Executive Officer Par Nijhawan, MD, is scheduled to present on Wednesday, April 17 at 11:00 am ET. To meet with Edesa management during the conference, please utilize the conference's online portal or contact the company directly at investors@edesabiotech.com.
Edesa首席執行官Par Nijhawan醫學博士定於美國東部時間4月17日星期三上午11點出席會議。要在會議期間與埃德薩管理層會面，請使用會議的在線門戶網站或直接通過 investors@edesabiotech.com 與公司聯繫。
About Edesa Biotech
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Edesa is also planning to file an investigational new drug application for a future Phase 2 study of paridiprubart for pulmonary fibrosis. For its dermatology assets, the company has received regulatory approval to conduct a Phase 2 trial of its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. Sign up for news alerts. Connect with us on X (Twitter) and LinkedIn.
關於 Edesa Biotech
Edesa Biotech, Inc.（納斯達克股票代碼：EDSA）是一家臨床階段的生物製藥公司，正在開發治療炎症和免疫相關疾病的創新方法。該公司最先進的候選藥物是EB05（paridiprubart），這是一種單克隆抗體，專爲涉及先天免疫反應失調的急性和慢性病適應症而開發。Edesa目前正在評估一項3期研究中的EB05作爲急性呼吸窘迫綜合症（ARDS）的潛在治療方法，急性呼吸窘迫綜合徵是一種危及生命的呼吸衰竭。Edesa還計劃爲未來的paridiprubart治療肺纖維化的2期研究提交研究性新藥申請。就其皮膚科資產而言，該公司已獲得監管部門的批准，可以對其EB06（抗CXCL10）單克隆抗體進行二期試驗，白癜風是一種改變生活的自身免疫性疾病，會導致皮膚在貼片中失去顏色。此外，Edesa正在開發一種SplA2抑制劑EB01（daniluromer），用於局部治療慢性過敏性接觸性皮炎（ACD），這是一種常見的職業性皮膚病。註冊接收新聞提醒。通過 X（推特）和 LinkedIn 聯繫我們。
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Edesa 前瞻性陳述
本新聞稿可能包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性陳述。前瞻性陳述可以通過使用 “預期”、“相信”、“計劃”、“估計”、“期望”、“打算”、“可能”、“將”、“可能”、“應該”、“可能”、“可能”、“可能”、“潛在” 或 “繼續” 等詞語以及變體或類似表述來識別。讀者不應過度依賴這些前瞻性陳述，這些陳述並不能保證未來的表現。無法保證前瞻性陳述會被證明是準確的，因爲所有這些前瞻性陳述都涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致實際業績或未來事件與前瞻性陳述存在重大差異。此類風險包括：Edesa獲得監管部門批准或成功將其任何候選產品商業化的能力；可能無法獲得足夠資本爲Edesa的運營提供資金的風險，或可能無法以對Edesa商業不利的條件提供；Edesa的候選產品可能無法有效對付其臨床試驗中測試的疾病的風險；Edesa未能遵守與第三方簽訂的許可協議條款的風險；因此，失去了使用關鍵知識的權利其業務中的財產、Edesa保護其知識產權的能力、提交的時機和成功程度、監管文件的接受和批准以及公共衛生危機的影響。這些決定實際業績的因素中有許多超出了公司的控制或預測能力。有關與Edesa業務相關的其他風險和不確定性的討論，請參閱Edesa向美國證券交易委員會和不列顛哥倫比亞省證券委員會提交的上市公司報告。所有前瞻性陳述均自本文發佈之日起作出，可能會發生變化。除非法律要求，否則Edesa不承擔更新此類聲明的義務。
CONTACT:
Gary Koppenjan
Edesa Biotech, Inc.
(289) 800-9600
investors@edesabiotech.com
聯繫人：
Gary Koppenjan
Edesa Biotech, Inc.
(289) 800-9600
investors@edesabiotech.com
SOURCE: Edesa Biotech
來源：Edesa Biotech
譯文內容由第三人軟體翻譯。